Holland Capital Announces Successful Exit of Defibrion to IK Partners
Amsterdam/Groningen, 23 July 2024 – Holland Capital is proud to announce that IK Partners (IK) has signed an agreement to acquire our portfolio company, Defibrion. Since 2019, Defibrion’s management team has successfully collaborated with Holland Capital. The shares of Defibrion are being sold to IK and the company’s management team. IK is a leading European private equity firm focused on investments in the Benelux, DACH, France, Nordics and the UK.
Defibrion: A Leading Provider in AED Distribution and Safety Products
Founded in 2008 by the current CEO Joshua Valkenier and based in Groningen, Defibrion is a market leader in the distribution of automated external defibrillators (AEDs) and related safety products. The company offers a wide range of products and services aimed at enhancing workplace safety. With over 6,400 customers worldwide, Defibrion serves as a one-stop-shop for emergency response needs. Its customer base, which includes more than 900 resellers in Europe and North America, comprises various end users such as offices, sports clubs, and government institutions.
Strategic Growth and Expansion
Since 2019, Holland Capital has been involved with Defibrion as a shareholder. They actively supported the management in professionalizing the organization and the strategic development of the company. Through a successful buy-and-build strategy and a focus on geographical expansion in Western Europe, Defibrion has been able to grow successfully.
Defibrion is now on the brink of a new phase in its development, which will be supported by IK. In this new phase, Defibrion will further scale up its existing operations, broaden its offerings, and expand into new markets. The strategic plan also includes exploring further buy-and-build opportunities to promote consolidation in the fragmented market of AEDs and related safety products.
Joshua Valkenier, founder and CEO of Defibrion, said: “When Holland Capital joined Defibrion as a shareholder in 2019, we had the ambition to internationalize, professionalize, and further expand our organization. I am pleased that we have achieved this and am grateful to Holland Capital for the pleasant and successful collaboration.”
Ewout Prins, managing partner of Holland Capital, commented: “The collaboration with Joshua Valkenier and the Defibrion team was both successful and enjoyable. When we joined, we were convinced that the AED market offered interesting growth opportunities, and Defibrion has demonstrated this. Their dedication and vision have played a crucial role in achieving this growth. We are proud to have contributed to the successful growth of Defibrion and its life-saving products. We wish the team much success in this next phase of growth.”
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and strives for an open, sustainable, and professional relationship with the management teams of the companies they invest in, with the common goal of realizing growth. Holland Capital has offices in Amsterdam and Düsseldorf. With specialized sector teams, it focuses on the Healthcare, Technology, and Agrifood-Tech sectors. They understand the dynamics and opportunities, and have an extensive network in these sectors.
Holland Capital invests in AMP Groep, an innovative service provider in logistics and identification
Holland Capital invests in AMP Groep, an innovative service provider in logistics and identification Amsterdam / Houten, October 6th, 2020 – Investment firm Holland Capital invests in AMP Groep, an innovative service provider active in the logistics and identification...
U-Needle secures growth financing for the global rollout of its Bella-mu product range
Amsterdam/Enschede, 1st of October 2020 – Holland Capital invests in U-Needle with Waterman Ventures and along with existing shareholders including UT International Ventures incubator fund. U-Needle has developed Bella-mu, a range of needles created for intradermal...
Yenlo and Fides join forces
Amsterdam, 21 September 2020 – Our portfolio company Yenlo (the integration specialist in the field of API and ESB technology) and Fides (the AFAS migration and integration partner for healthcare and education) join forces to support the integration for customers with...
Holland Capital invests in innovative primary care IT platform HealthConnected
Amsterdam/Alkmaar, September 1st, 2020 – Holland Capital, a Dutch based investment firm, invests in HealthConnected, a healthcare IT platform for the primary care market. This investment enables HealthConnected to focus on the expansion to new regions in the...
Sirius Medical raises €4.4M to launch Sirius Pintuition
Sirius Medical raises €4.4M to launch Sirius PintuitionAn innovative breast cancer localization technology Amsterdam, July 14th, 2020 – Investment company Holland Capital invests 4.4 million euros in Sirius Medical together with BOM Brabant Ventures and Curie Capital....
Sirius Medical announces CE mark for Pintuition: a non-radioactive localization system to improve breast cancer surgery
Sirius Medical announces CE mark for Pintuition: a non-radioactive localization system to improve breast cancer surgery Eindhoven, June 16, 2020 – Sirius Medical, a MedTech startup, announced that it has received CE mark approval for Sirius Pintuition. With its debut...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl